FDA Smacks Down Vanda's Bid To Block Fanapt Generics
The FDA’s decision rejected a citizen petition that D.C.-based Vanda filed in September to thwart proposed copycats of Fanapt, the most popular of its two approved products. Vanda had argued that its three-year exclusivity for long-term use of Fanapt bars generics until 2019. But the FDA disagreed.
Specifically, the FDA on Wednesday shot down assertions...
To view the full article, register now.